Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

Benzer Materyaller

• Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
  Yazar:: Elghissassi, Ibrahim, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre
  Yazar:: Ma, K., ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer
  Yazar:: Hirsh, Vera
  Baskı/Yayın Bilgisi: (2012)
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR
  Yazar:: Créquit, Perrine, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Intrapartum management of twin gestation: what is best for the second and the small?
  Yazar:: Gandhi, J., ve diğerleri
  Baskı/Yayın Bilgisi: (1983)